Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

Exclusion Criteria

• •Known or suspected brain metastases.
• •Participants with an active infection, Any other infection requiring systemic treatment or latent infection.
• •Participants with clinically significant comorbidity(s).
• •History of treatment for, or suspicion or confirmed interstitial lung disease (ILD) at baseline.
• •Condition being treated with systemic corticosteroids or immunosuppressive therapy during IPH4502 treatment.
• •Thromboembolic event requiring anticoagulation therapy ≤14 days prior to the first dose of IPH4502.
• •Clinically significant cardiovascular disease and/or cardiac repolarization abnormality.
• •Participants with symptomatic heart failure, Acute coronary syndromes
• •Participant is receiving or has received anticancer therapy prior to enrolment that may have impact on the assessment of IPH4502.
• •Major surgery ≤28 days and minor surgery ≤7 days prior to first dose of IPH4502 or 6 months for coronary artery bypass surgery.
• •Concomitant medications or vaccines : Live-attenuated vaccines ≤ 6 weeks prior to first dose of IPH4502; systemic corticosteroids or other immunosuppressive agents within 14 days prior to the first dose of IPH4502; systemic use of moderate or strong CYP 3A4 inhibitors; systemic use of moderate or strong CYP 3A4 inducers.